Basic Information
Samsca
Regulatory Information
EMEA/H/C/000980
Authorised
August 2, 2009
May 28, 2009
16
July 1, 2022
Company Information
Netherlands
Herikerbergweg 292 1101 CT Amsterdam
Otsuka Pharmaceutical Netherlands B.V.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion (SIADH).
Overview Summary
Samsca is a medicine for treating abnormally low levels of sodium in the blood in adults with a condition called ‘syndrome of inappropriate antidiuretic hormone secretion’ (SIADH). In SIADH, an excessive amount of the hormone vasopressin makes the patient produce less urine and thereby retain more water in the body, which dilutes the concentration of sodium in the blood. Samsca contains the active substance tolvaptan.